



# **Inventory and Analysis of Increased Uncertainties of Health Care Providers, Patients and other Stakeholders**

**(Executive summary – document under review by consortium)**

February 2018

*The work leading to these results was conducted as part of the ADAPT SMART consortium (Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes). For further information please refer to [www.adaptsmart.eu](http://www.adaptsmart.eu). This paper is the result of the collective input from working group D3.04 and only reflects the views of the authors.*

*This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115890. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.*



## **Executive Summary**

ADAPT SMART was set up as a Coordination and Support Action under the European Innovative Medicines Initiative (IMI). The objective of ADAPT SMART was to establish a multi-stakeholder enabling platform to facilitate and accelerate the availability of MAPPs and engage a dialogue with relevant stakeholders for the coordination of MAPPs (Medicines Adaptive Pathways to Patients) related activities. Like the EMA Adaptive Pathway, MAPPs seeks to foster access to beneficial treatments for the right patient groups at the earliest appropriate time in the product life-span in a sustainable fashion. As part of the project which has looked at which product could be worth entering the MAPPs framework (deliverables D2.05 and D3.02) according to predefined engagement criteria (deliverable D2.03), Work Package 3 interviewed a few Health Care Providers and patients' organisations to understand better what could be their issues and uncertainties when confronted with MAPPs.

Given the small sample size of interviewees (10 HCPs and 5 patients' organisations), any conclusion must be interpreted with caution. However, given the interviewees, previous interactions and the literature, we believe these interactions have provided a useful snapshot of what would be HCPs and patients' organisations main issues and uncertainties when confronted with a MAPPs product.